Dystrophic epidermolysis bullosa research is prioritising advanced therapies over patient needs A letter to the editor of the Journal of the American Academy of Dermatology highlights the …
Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
RDEB recognized as most severe form of all epidermolysis bullosa conditions June 13, 2014 Fibrocell Science, Inc., an autologous cell therapy company primarily focused on …